Core Insights - Wellgistics Health, Inc. has launched the diabetes prescription drug Brenzavvy® targeting 33 million Americans diagnosed with type II diabetes, primarily through its network of 6,500 independent pharmacies [1][4] - The SGLT-2 inhibitor market, which includes drugs like Jardiance®, reached sales of $16.8 billion in 2024 and is projected to grow to $28.9 billion by 2033, with the U.S. accounting for 40.8% of this market [2][4] - The proprietary EinsteinRx™ artificial intelligence platform will assist pharmacists in optimizing therapy selection and educating providers about Brenzavvy's benefits compared to other SGLT-2 inhibitors [2][3] Company Overview - Wellgistics Health integrates its EinsteinRx™ AI platform with a blockchain-enabled smart contracts platform, PharmacyChain™, to enhance the prescription drug dispensing process [4][5] - The company aims to improve patient access to medications while providing revenue opportunities for pharmacists through patient education on Brenzavvy [3][4] - The launch of Brenzavvy establishes a new model for next-generation drugs that offer specific advantages over established market leaders [4] Market Context - A significant gap exists in the prescription of SGLT-2 inhibitors, with only 11.9% of eligible diabetic patients receiving guideline-recommended prescriptions, indicating a need for improved care [2] - The launch of Brenzavvy is positioned to address the high out-of-pocket costs faced by many patients, particularly those who are uninsured or underinsured [4]